This week in Drug Discovery (9-13 November)
News round-up for 9-13 November 2026 by Diana Turner, Deputy Editor at DDW.
From pharma and AI collaborations to financing deals that will enable expansion, this week’s news roundup focuses on the theme of partnership, a key factor in success in the drug discovery and development industry.
The top stories:
Pierre Fabre and XtalPi team up on drug discovery
Pharmaceutical company Laboratoires Pierre Fabre and AI platform company XtalPi have announced a collaboration to discover novel drug candidates across oncology, rare diseases, and dermatology.
ProBio and AbTis partner on next-generation antibody-drug conjugate
CRDMO ProBio and South Korean biotechnology company AbTis have agreed an exclusive global licensing agreement for the development of antibody-drug conjugates (ADCs).
Boehringer Ingelheim puts China strategy into action with SBP deal
Boehringer Ingelheim and China’s SBP Group have entered a strategic multi-programme agreement with to advance potential cancer treatments based on antibody-drug conjugate (ADC) and T-cell engager (TcE) technologies.
Lonza signs agreement to acquire US CDMO network from Merck
Lonza has signed a definitive agreement to acquire five CDMO manufacturing sites in the US from Merck (Darmstadt, Germany) at a total enterprise valuation in the low- to mid-triple-digit millions Swiss francs.
Biotech raises a €31.5m seed round to develop mRNA therapeutics
SRTD Biotech has announced the successful completion of an oversubscribed €31.5 million seed financing round.
